Argus analyst David Coleman upgraded Allscripts to Buy from Hold with a $26 price target. The company’s cloud-based solutions have helped to meet the changing needs of patients and healthcare providers during the pandemic, and its increasing margins should continue to benefit from its fast-growing Veradigm business, the analyst tells investors in a research note. Allscripts shares also appear "attractively valued" at current prices near $18, in the lower half of their 52-week range of $13-$23, Coleman adds.
Published first on TheFly
